THE CHAEUM (Chaeum Premium) is Hugel's four-grade HA filler, made by Across in Korea. Premium No.1 through No.4 are dual 1.1 mL syringes with 0.3% lidocaine, stepping from 30G superficial work to 23G deep volume. Clinics ordering Chaeum Premium wholesale restock that ladder in one mixed-SKU quote.
THE CHAEUM Premium is Hugel’s four-grade HA restock from Across in Chuncheon: No.1 through No.4, dual 1.1 mL syringes, 0.3% lidocaine, stepping 30G to 23G. Clinics buying Chaeum Premium wholesale mix those grades in one MOQ quote from Korean B2B export — No.2 as the usual core, with No.1, No.3, and No.4 filling the plane tails.
Direct partnership with Korean supply and high-volume procurement keep B2B positioning competitive while cartons stay factory-sealed. Send the No.1–4 split, destination, and any Pure or Shape 10 add-on; that mix is what we pack.
Across manufactures in Chuncheon. Hugel Inc. is the named seller. Premium No.1–4 share dual 1.1 mL and lidocaine 0.3%, then differ by HA concentration, official Pa·s band, packed needle, and Across plane. One Korean export order can refill the ladder.
Unopened Premium syringes store at 2–25°C with a 24-month shelf life. Do not freeze. Pack and restock this gel inside that window — not as a frozen or 2–8°C toxin shipment.
We quote the four Premium grades together. Reliable wholesale pricing here comes from Korean-side volume and a direct export path, not from cut-price language. Ask for the MOQ that matches monthly No.2 rotation plus the lighter and firmer tails.
Chaeum Premium is not a US PMA dermal filler. Grey “FDA approved” badges on this gel, or Revolax CE copied onto a Premium carton, are a reason to walk away.
United Kingdom, Germany, France, Italy, Spain, Poland, Albania
United Arab Emirates (Dubai), Saudi Arabia, Qatar, Kuwait, Turkey
United States, Canada, Mexico, Brazil, Colombia, Argentina
Japan, Australia, Thailand
The United States appears in that list as a shipping destination for professional buyers who already hold a lawful import route. That is not a US PMA. Hugel’s HA-filler franchise map is not a SKU-level register of every Premium carton in every country.
HA gels move as quote-led B2B export, not as a public checkout. The sequence below is the real handoff: four-grade mix first, then stock, then packing inside 2–25°C.
Tell us how many Premium No.1, No.2, No.3, and No.4 packs you need, the destination country, and whether Pure 1.0 mL or Shape 10 should sit beside the facial mix.
We check current Korean supply and remaining shelf life against Across’s 24-month unopened window, and whether the requested grade split can ship together.
After you confirm quantities, the order is created with destination, packing notes, and HA handling inside 2–25°C.
Once payment is confirmed, reserved cartons move into packing. HA gels are not frozen for dispatch. Freezing is a discard condition.
Confirmed orders leave by FedEx, EMS, air-freight branch handoff, or container for larger clinic or distributor lots, depending on route and volume.
After arrival, we help plan the next No.1–4 restock from usage speed so the No.2 core and the No.1 / No.3 / No.4 tails do not drift out of balance.
Core wholesale SKUs are the four Premium grades. All four are lidocaine 0.3% dual 1.1 mL packs. What changes is HA concentration (only No.1 is 24 mg/mL), official viscosity in Pa·s, packed needle, and Across-stated plane. Integers 1–4 are ordered grades. They are not G′ in pascals and they are not a “cross-linking rate 1/4–4/4.”
| Variant | Best for | Depth / Area | Needle | Lidocaine | Procurement note |
|---|---|---|---|---|---|
| Chaeum Premium No.1 | Superficial-dermis facial-wrinkle work on the Across depth ladder | Superficial dermis (Across) | 4 × 30G | 0.3% in both 1.1 mL syringes | Lightest Premium grade. Quote it as the fine-plane tail next to a No.2 core, not as a chin gel. |
| Chaeum Premium No.2 | Mid/deep dermis to subcutis restock; usual clinic core grade | Mid/deep dermis – subcutaneous (Across) | 4 × 27G | 0.3% in both 1.1 mL syringes | Highest-rotation SKU for most chairs. Build the mixed quote around No.2, then add No.1 and No.3/No.4 tails. |
| Chaeum Premium No.3 | Deep subcutaneous facial-wrinkle volume on the Across ladder | Deep subcutaneous (Across) | 4 × 25G | 0.3% in both 1.1 mL syringes | Firms the mix for deeper planes. Ask for it as a No.2 companion, not as a 10 mL body SKU. |
| Chaeum Premium No.4 | Deep subcutaneous structural work; firmest Premium grade | Deep subcutaneous (Across) | 4 × 23G | 0.3% in both 1.1 mL syringes | Firmest dual 1.1 mL grade. Across packs 23G, consistent with Lee 2020 measuring a high 27G extrusion force on No.4. |
Specs: HA 24 mg/mL + lidocaine 0.3%, 1.1 mL × 2, 4 × 30G, official viscosity 80–199 Pa·s
No.1 is the only Premium grade at 24 mg/mL HA. Across packs two 1.1 mL lidocaine syringes and four 30G needles for the superficial dermis. Official viscosity is 80–199 Pa·s, which is not G′. Independent G′ under Lee et al., Dermatol Surg 2020 (PMID 30883477) is 76 Pa in that lab method.
Specs: HA 20 mg/mL + lidocaine 0.3%, 1.1 mL × 2, 4 × 27G, official viscosity 200–399 Pa·s
No.2 is the workhorse Premium grade: 20 mg/mL HA, 0.3% lidocaine, dual 1.1 mL, four 27G needles. Official viscosity is 200–399 Pa·s. Independent G′ in PMID 30883477 is 146 Pa. Yi 2023 (PMID 37156109) later reported 185.8 Pa for No.2 under a different protocol — do not average those figures into an official G′.
Specs: HA 20 mg/mL + lidocaine 0.3%, 1.1 mL × 2, 4 × 25G, official viscosity 400–549 Pa·s
No.3 stays at 20 mg/mL HA with 0.3% lidocaine in dual 1.1 mL syringes, packed with four 25G needles for deep subcutis. Official viscosity is 400–549 Pa·s. Independent G′ in PMID 30883477 is 232 Pa. Hong 2023 (PMID 37313624) measured Premium No.3 at 300.6 ± 0.6 Pa on an amplitude-sweep protocol — a different assay, not a replacement official number.
Specs: HA 20 mg/mL + lidocaine 0.3%, 1.1 mL × 2, 4 × 23G, official viscosity 550–700 Pa·s
No.4 is the firmest Premium presentation: 20 mg/mL HA, 0.3% lidocaine, dual 1.1 mL, four 23G needles, deep subcutis. Official viscosity is 550–700 Pa·s. Independent G′ in PMID 30883477 is 340 Pa. In that same 41-filler study, No.4 recorded the highest 27G injection force at 54.8 N — which is why the pack ships 23G, not a marketing G′ index.
Across still lists Pure No.1–4: 20 mg/mL HA, no lidocaine listed, 1.0 mL dual syringes, same 30G / 27G / 25G / 23G needle families, “hypodermic” plane. Quote Pure when a chair needs a lidocaine-free 1.0 mL cousin — not as a fifth Premium viscosity.
Shape 10 is 20 mg/mL, lidocaine-free, 10.0 mL, one syringe. Across application part is penis; Hugel R&D lists penile enlargement in 2017; 2026 Hugel copy also calls it a large-volume body filler. It is not a face SKU.
The Chaeum Signature 1–4 launched 20 July 2026 with Across MPC (manufacturer claim: multi-purified crosslinking, >50% less crosslinking agent versus the conventional Across process). Official site: MFDS-approved for temporary improvement of facial wrinkles; residual BDDE managed ≤2 ppm. HA mg/mL, needle, volume, and G′ were not listed on the Across English SKU table as of the dossier date. Hugel JPM 2026 names a “Low BDDE / Multi Phase Crosslink” filler with later launch targets — do not assume that slide is already every Signature carton.
Lee 2019/2020 (PMID 30883477) is independent lab rheology for the four-grade G′ ladder; the 2018 Hugel leaflet is manufacturer artwork with in-house G′ and is not a current IFU. Hugel AR 2025 and JPM 2026 are corporate files.
Independent laboratory rheology of 41 marketed HA fillers (PMID 30883477). Chaeum No.1–4 G′ under that method: 76 / 146 / 232 / 340 Pa. Not a Hugel brochure and not labelled G′ on the IFU.
Open Lee 2019/2020 rheology paperHugel English 7-page leaflet (DMR, TCU-BR180308ENG), TradeKorea host, Hugel artwork. Covers Dermalax and THE CHAEUM Premium. Not a current pack IFU. In-house G′ on the Chaeum table (80±15 / 180±15 / 300±15 / 400±15 Pa) does not replace Lee 2019 independent 76 / 146 / 232 / 340 Pa. “CE Certified” in this PDF sits on the Dermalax table — not a Chaeum Premium carton mark. Duration and phase-angle plots are in-house or Chung-Ang 2014 in vivo, not labelled duration months.
Open 2018 Hugel leafletCorporate English annual report covering Hugel quality systems and the HA filler franchise (The Chaeum, Revolax, Dermalax, Persnica). This is a company filing, not a Chaeum IFU.
Open Hugel Annual Report 2025Official IR deck (16 January 2026). Pipeline language names a Low BDDE / Multi Phase Crosslink filler with later launch targets — that slide is not proof the commercial Signature carton is already in every market. Not an IFU.
Open JPM 2026 presentationOriginality is a carton-and-label job: manufacturer seals, tradename, lot, expiry, dual 1.1 mL, and lidocaine 0.3%. Buyers verify those visual marks on arrival rather than relying on extra paperwork promises.
Accept THE CHAEUM / Chaeum Premium artwork you ordered. Revolax, Dermalax, and Persnica are related Across/Hugel HA names with different licences. Do not treat a sister carton as the Premium pack unless that tradename was on the quote.
Match lot number and expiry between the outer carton and both 1.1 mL syringes. Do not use product past expiry or with an unknown storage history.
Premium packs are two 1.1 mL syringes with lidocaine 0.3%. Pure is a different 1.0 mL lidocaine-free family. A single-syringe or unlabelled lidocaine swap is a refuse signal.
Chaeum Premium is not an FDA PMA dermal filler. Hugel’s 2024 US FDA story is Letybo toxin, not this gel. Grey “FDA approved” badges are a reason to walk away, not a selling point.
Official styling is THE CHAEUM®. Export and clinic speech also use The Chaeum, Chaeum Premium, and CHA EUM on some packs. The line is a family of sterile, prefilled, injectable, BDDE-crosslinked hyaluronic acid gels for soft-tissue augmentation. Across’s English product page classifies the products as a biomaterial graft and prosthesis used for temporary improvement of facial wrinkles, and as a medical device.
The manufacturer is Across Co., Ltd., Chuncheon, Gangwon-do, Republic of Korea (Hugel Inc. affiliate). The seller named on the official The Chaeum brand site is Hugel Inc. (휴젤주식회사). Grey-shop pages that print “Hugel Pharma Co., Ltd.” as the current listed manufacturer are not how we write the legal entities. Plant campus: 23, Geodudanji 1-gil, Dongnae-myeon, Chuncheon-si, Gangwon-do.
Chaeum Premium is an HA gel from Across / Hugel, not a botulinum toxin.
Do not merge Premium SKUs with REVOLAX or DERMALAX. Across’s own English homepage: THE CHAEUM is a domestic brand; REVOLAX and DERMALAX are export brands. Hugel IR language that groups The Chaeum’s “export names” as Revolax, Dermalax, and Persnica is financial grouping, not proof that a Premium No.3 carton is the same labelled device as Revolax Deep.
Hugel’s quality page names UFHT (Unit-Form High Technology) as the crosslinking process for sodium hyaluronate. Treat UFHT as a manufacturer process name, not as a measured G′. Official brand pages publish viscosity bands in Pa·s. They do not publish G′. Independent G′ belongs to named papers, not to the IFU.
Hugel describes UFHT as crosslinking of sodium hyaluronate for a high-elasticity gel. Annual-report quality language also describes room-temperature crosslinking and ultra-high-temperature sterilisation followed by rapid cooling. These are manufacturer process claims. They are not a published honeycomb protocol and they are not a G′ certificate.
Signature 1–4 uses a different Across construct: MPC (Multi-Purified Crosslinking), with a Hugel launch claim of more than 50% less crosslinking agent versus the conventional Across process and a multi-week purification. That claim is for Signature, not proven for Premium.
Premium gels are BDDE-crosslinked sodium hyaluronate with 0.3% lidocaine in dual 1.1 mL syringes. No.1 is 24 mg/mL HA; No.2–4 are 20 mg/mL. Hugel quality pages describe EP-spec sodium hyaluronate, with HA certified to MFDS and EDQM — manufacturer raw-material claims.
Hugel’s Korean The Chaeum page and iamthechaeum.com state eight dialysis cycles and residual BDDE managed to the MFDS criterion of ≤2 ppm. That is a manufacturer / licence-criterion claim, not an independent lot assay. Grey-shop “<0.5 ppm” or “<0.03 EU/mL endotoxin” figures are not Hugel/Across public-page specs. Reconstitution is not applicable: the gel is prefilled. Do not dilute.
iamthechaeum.com publishes complex viscosity (η*) bands for Premium only. These are manufacturer-stated Pa·s ranges. They are not storage modulus.
| Premium grade | Official viscosity (Pa·s) | HA | Independent G′ (PMID 30883477) |
|---|---|---|---|
| No.1 | 80–199 | 24 mg/mL | 76 Pa |
| No.2 | 200–399 | 20 mg/mL | 146 Pa |
| No.3 | 400–549 | 20 mg/mL | 232 Pa |
| No.4 | 550–700 | 20 mg/mL | 340 Pa |
Lee W et al., Dermatol Surg 2020;46:41–49 (PMID 30883477) is the only G′ ladder we print for all four grades: one laboratory, one method, 25 °C. Hong 2023 (PMID 37313624) and Yi 2023 (PMID 37156109) used different protocols and must not be averaged into an “official G′.” In-house brochure tables such as 80±15 / 180±15 / 300±15 / 400±15 Pa are not labelled G′ and do not replace Lee 2019.
Labelled Korean indication (Hugel brand page, iamthechaeum.com, Across boilerplate): a tissue-repair biomaterial that uses lidocaine-containing crosslinked hyaluronic acid injected subcutaneously to temporarily improve facial wrinkles in adults by physical restoration. Hugel R&D additionally lists The Chaeum (+Lidocaine) — central facial volume increase — approved 2020. Across application part for all four Premium SKUs is “Facial wrinkles.”
| Grade | Across-stated plane | Packed needles | Labelled indication |
|---|---|---|---|
| Premium No.1 | Superficial dermis | 4 × 30G | Facial wrinkles in adults; 2020 Hugel listing also includes central facial volume |
| Premium No.2 | Mid/deep dermis – subcutaneous | 4 × 27G | Facial wrinkles in adults; Across plane mid/deep dermis to subcutis |
| Premium No.3 | Deep subcutaneous | 4 × 25G | Facial wrinkles in adults; Across plane deep subcutaneous |
| Premium No.4 | Deep subcutaneous | 4 × 23G | Facial wrinkles in adults; Across plane deep subcutaneous (23G pack) |
For clinics already comparing Dermal fillers wholesale lines, the Across depth ladder is the only manufacturer-named plane sequence we retrieved. Use the packed needle that ships with the grade. Lee 2020 measured Chaeum No.4 extrusion at 54.8 N through a 27G — consistent with Across packing 23G for No.4. Extra-facial papers (Park 2024 larynx) are off-label relative to facial-wrinkle labelling and are not protocolised here as a face map.
Chaeum Premium is supplied ready to inject. Reconstitution is not applicable. Do not dilute. Single-use, sterile, do not reuse. Inspect package integrity, expiry, gel homogeneity, and needle hub fit before opening. Discard unused gel.
| Pack fact (Across) | Premium No.1 | No.2 | No.3 | No.4 |
|---|---|---|---|---|
| Syringes | 1.1 mL × 2 | 1.1 mL × 2 | 1.1 mL × 2 | 1.1 mL × 2 |
| Needles in pack | 4 × 30G | 4 × 27G | 4 × 25G | 4 × 23G |
| Lidocaine | 0.3% | 0.3% | 0.3% | 0.3% |
Local pack always prevails: HA concentration, lidocaine, needle, volume, labelled plane, and storage on the carton in the clinic supersede any cross-market table on this page. Keep hyaluronidase in the room as clinic protocol for any HA filler. Product-specific hyaluronidase dose-response curves were not found on Hugel/Across public pages; treat Premium as a standard BDDE-crosslinked HA that is hyaluronidase-sensitive in principle.
Hugel’s brand page says efficacy and safety were “demonstrated in clinical trials” for temporary facial-wrinkle improvement. The pivotal n, design, and endpoint table were not published on Hugel/Across public pages retrieved 30 August 2026. Indexed papers that name Chaeum are mostly rheology and cohesion; the one named human interventional study is off-label laryngoplasty.
| Source | What it is | Numbers cited here |
|---|---|---|
| Lee et al., Dermatol Surg 2020, PMID 30883477 | Lab rheology, 41 marketed HA fillers | G′ 76 / 146 / 232 / 340 Pa for No.1–4; No.4 injection force 54.8 N (27G) |
| Hong et al., J Cosmet Dermatol 2023, PMID 37313624 | Amplitude sweep, different protocol | Premium No.3 initial G′ 300.6 ± 0.6 Pa — not averaged into Lee |
| Yi et al., JPRAS 2023, PMID 37156109 | Rheology comparator in a Giselleligne RCT | No.2 G′ 185.8 Pa / G″ 33.4 Pa — not a Chaeum efficacy RCT |
| Kim, Lee, Yang, Arch Plast Surg 2024 | Cohesion battery | Sample 2 = Premium No.2, lot BLC21000A |
| Park & Kim 2024, KCT0007597 | Phase II injection laryngoplasty, off-label | Premium No.2, n=10, median 1.05 mL; peak ~3 months; not a facial pivotal |
Lee 2020 G′ and companion values, same method:
| Product | G′ (Pa) | G″ (Pa) | tan δ | Cohesiveness (N) | 27G injection force (N) |
|---|---|---|---|---|---|
| Chaeum No.1 | 76 | 28 | 0.3733 | 0.4888 | 14.7 |
| Chaeum No.2 | 146 | 29 | 0.2036 | 0.6716 | 34.3 |
| Chaeum No.3 | 232 | 52 | 0.2200 | 0.7474 | 37.2 |
| Chaeum No.4 | 340 | 68 | 0.2013 | 0.9180 | 54.8 |
Park JH, Kim MS, J Korean Soc Laryngol Phoniatr Logop 2024;35(1):30–34: Premium No.2, Across, Chuncheon; two institutions; MFDS clinical-trial approval No. 1353; funded in part by Hugel, Inc. Adults with unilateral vocal-cord paralysis; trans-cricothyroid, 25G; GRBAS improved through 6 months; many secondary measures peaked at 3 months and eased by 6 months; no adverse effects in 10/10. Off-label relative to facial-wrinkle labelling. Not an FDA injection-laryngoplasty approval. Not a facial NLF n.
The pack IFU in the carton prevails for indication, duration, and handling. Hugel labels temporary improvement of facial wrinkles; official pages do not publish a month figure. An English IFU PDF was not hosted on manufacturer domains as of 30 August 2026. No split-face NLF or midface RCT with a reported n, and no ClinicalTrials.gov NCT for Chaeum facial filler, appears on those public pages. Revolax Deep trials are a sister-brand dataset, not Chaeum Premium pivotal data.
Licence paths below are the ones we sourced. Sister-brand CE marks and Hugel’s toxin FDA date belong to those other cartons, not to this gel.
| Jurisdiction | What is sourced | What is not sourced |
|---|---|---|
| Korea MFDS | THE CHAEUM authorised as biomaterial graft & prosthesis, April 2014. Across manufacturing-product authorisation No. 14-1762 (October 2014). Residual BDDE ≤2 ppm as MFDS licence criterion. Signature: Hugel/iamthechaeum state MFDS approval (launch 20 July 2026). | Exact item-permit digits per Premium No.1–4 SKU — not independently pulled from the MFDS UDI database. Grey-shop “KFDA 3-2021-8521” is not used. |
| United States FDA | Hugel’s 2024 US FDA approval on the corporate timeline is Letybo toxin, not an HA filler. Hugel about-us “Authorization for HA Fillers” list did not include the United States (retrieved 30 August 2026). | No PMA, P-number, or 510(k) for Chaeum / Persnica / Across facial HA. Not a US-approved dermal filler pack. |
| Europe CE / MDR | Across documents CE for Dermalax (2012) and lidocaine HA (2015). Hugel Korean brand page: REVOLAX “certified in Europe.” Hugel quality page states CE at filler-franchise level. JPM 2026 flags “MDR transition for fillers” as future work. | CE / MDR notified-body number for a Chaeum Premium carton was not retrieved. This page does not print a CE mark or NB digits for Premium. |
| China NMPA | Persnica marketing approval announced 19 April 2022 (Hugel / Korea Biomedical Review). Hugel AR: “The Chaeum (export name: Persnica).” | Proof that every Premium 1–4 SKU is the NMPA pack. Persnica is not a fifth Premium viscosity grade. |
iamthechaeum advertising-review IDs (Premium 62026-I10-24-2986; Signature 62026-I10-24-2988; valid to 16 July 2029) are Korean advertising-review numbers, not CE notified-body numbers. Hugel about-us country lists for HA fillers are franchise-level authorisations (Revolax / Dermalax / Persnica / Chaeum depending on market), not a SKU-level register of Premium cartons.
Across storage for Premium is 2–25°C with a 24-month unopened shelf life. Do not freeze; that is standard HA handling, and the carton IFU prevails.
The carton IFU prevails for contraindications and handling. Class-typical HA + lidocaine cautions may still apply in the clinic. Vascular-occlusion preparedness is clinic protocol for any HA filler.
The frames below are before-and-after visual examples for nasolabial-fold planning and midface volume planning. They are illustrative product visuals, not labelled patient outcomes. Product-box photography in the hero gallery and the technology poster above are also not treatment outcomes.
Send the four-grade mix, destination, and whether you also want Pure 1.0 mL (no lidocaine) or Shape 10 as a non-face 10 mL SKU. MOQ and B2B pricing are quoted from that mix, not from a public cart. Most chairs build around No.2 and add No.1 plus No.3 or No.4 as tails.
No. Shape 10 is a 10.0 mL, lidocaine-free Across SKU. Hugel R&D lists penile enlargement (2017); Across names the application part as penis; 2026 Hugel copy also calls it a large-volume body filler. Do not treat it as a face syringe.
Signature 1–4 launched 20 July 2026 with Across MPC. Hugel/iamthechaeum state MFDS approval for temporary facial-wrinkle improvement and the same ≤2 ppm residual-BDDE claim. HA mg/mL, needle, volume, and G′ were not listed on the Across English SKU table as of 30 August 2026. Ask if you need it; do not assume Premium specs.
Keep unopened syringes at 2–25°C per Across. Labelled shelf life is 24 months unopened. This is an HA gel lane, not a 2–8°C toxin fridge. If stock sat near the lower bound, allow the syringe to equilibrate before injection and inspect gel homogeneity.
No. THE CHAEUM is a hyaluronic acid gel. Export uses temperature-aware packing inside the 2–25°C window. Do not freeze; that is standard HA handling, and the carton IFU prevails if it prints a stricter line.
No. Chaeum Premium is not a US PMA dermal filler; no PMA, P-number, or 510(k) for Chaeum / The Chaeum / Persnica facial HA was identified. The United States can still be a shipping destination for buyers who already hold a lawful import path — that is not PMA.
No. Across lists THE CHAEUM as a domestic brand and REVOLAX / DERMALAX as export brands. Hugel IR groups them for financial reporting. Different brand names, variant grids, and market licences. Persnica is the China NMPA tradename (April 2022), not a fifth Premium viscosity grade.
Check factory seals, THE CHAEUM tradename, lot number, expiry, dual 1.1 mL syringes, lidocaine 0.3%, and the packed needle family (30G / 27G / 25G / 23G). Compare carton and syringes. Authenticity is manufacturer packaging plus those visual marks — not a reseller FDA sticker.
No.2 — HA 20 mg/mL, lidocaine 0.3%, dual 1.1 mL, 4 × 27G, mid/deep dermis to subcutis, official viscosity 200–399 Pa·s. No.1 is the 24 mg/mL / 30G superficial-dermis grade. No.3 and No.4 are 20 mg/mL deep-subcutis grades with 25G and 23G.
No. Hugel/Across publish complex viscosity bands in Pa·s (No.1 80–199; No.2 200–399; No.3 400–549; No.4 550–700). That is not G′. Independent G′ from Lee et al., PMID 30883477, is 76 / 146 / 232 / 340 Pa under that method. Brochure ±15 Pa tables are in-house figures, not labelled G′.
Pure No.1–4 are manufacturer-listed 20 mg/mL gels with no lidocaine listed, 1.0 mL dual syringes, and the same 30G / 27G / 25G / 23G needle families. They are adjuncts, not the hero wholesale facial line. Premium is the lidocaine 0.3% / 1.1 mL ladder.
Hugel labels temporary improvement of facial wrinkles in adults. Official manufacturer pages do not publish a month figure.
The pivotal n, design, and endpoint table were not published on Hugel/Across public pages retrieved 30 August 2026. Hugel states efficacy and safety were demonstrated in clinical trials for temporary facial-wrinkle improvement. Revolax trial n is a sister-brand dataset, not Chaeum Premium data.
Park JH, Kim MS, 2024 (CRIS KCT0007597): Phase II injection laryngoplasty with The Chaeum Premium No.2, n=10, Hugel-funded in part. Off-label relative to facial-wrinkle labelling. Peak benefit around 3 months; some deterioration by 6 months; no adverse effects in 10/10. Not a labelled laryngoplasty indication and not a facial pivotal.
e.p.t.q. S100, S300 and S500 24 mg/mL HA fillers from Jetema, supplied as a three-grade Korean wholesale line for clinic restocking.
Neuramis wholesale HA filler portfolio supply for clinics that order Neuramis Light, Deep, and Volume variants in one planned bulk order.
Elasty D wholesale filler supply with Elasty D Plus options, PNET™ documentation, and B2B bulk order planning for aesthetic clinics.